Skip to main content

Advertisement

SpringerLink
Log in

Association of Biomarkers of Lipid Modification with Functional and Morphological Indices of Coronary Stenosis Severity in Stable Coronary Artery Disease

  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

Biomarkers of blood lipid modification and oxidative stress have been associated with increased cardiovascular morbidity. We sought to determine whether these biomarkers were related to functional indices of stenosis severity among patients with stable coronary artery disease. We studied 197 consecutive patients with stable coronary artery disease due to single vessel disease. Fractional flow reserve (FFR) ≤ 0.80 was assessed as index of a functionally significant lesion. Serum levels of secretory phospholipase A2 (sPLA2) activity, secretory phospholipase A2 type IIA (sPLA2-IIA), myeloperoxydase (MPO), lipoprotein-associated phospholipase A2 (Lp-PLA2), and oxidized low-density lipoprotein (OxLDL) were assessed using commercially available assays. Patients with FFR > 0.8 had higher sPLA2 activity, sPLA2 IIA, and OxLDL levels than patients with FFR ≤ 0.8 (21.25 [16.03–27.28] vs 25.85 [20.58–34.63] U/mL, p < 0.001, 2.0 [1.5–3.4] vs 2.6 [2.0–3.4] ng/mL, p < 0.01; and 53.0 [36.0–71.0] vs 64.5 [50–89.25], p < 0.001 respectively). Patients with FFR > 0.80 had similar Lp-PLA2 and MPO levels versus those with FFR ≤ 0.8. sPLA2 activity, sPLA2 IIA significantly increased area under the curve over baseline characteristics to predict FFR ≤ 0.8 (0.67 to 0.77 (95 % confidence interval [CI]: 0.69–0.85) p < 0.01 and 0.67 to 0.77 (95 % CI: 0.69–0.84) p < 0.01, respectively). Serum sPLA2 activity as well as sPLA2-IIA level is related to functional characteristics of coronary stenoses in patients with stable coronary artery disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

sPLA2:

Secretory phospholipase A2 activity

sPLA2-IIA:

Secretory phospholipase A2 activity type IIA

MPO:

Myeloperoxydase

Lp-PLA2:

Lipoprotein-associated phospholipase A2

OxLDL:

Oxidized low-density lipoprotein

References

  1. http://www.who.int/mediacentre/factsheets/fs310_2008.pdf.

  2. Libby, P., Ridker, P. M., & Hansson, G. K. (2009). Inflammation in atherosclerosis: from pathophysiology to practice. Journal of the American College of Cardiology, 54, 2129–2138.

    Article  PubMed  CAS  Google Scholar 

  3. Pratap, P., Gupta, S., & Berlowitz, M. (2012). Routine invasive versus conservative management strategies in acute coronary syndrome: time for a "hybrid" approach. Journal of Cardiovascular Translational Research, 5, 30–40.

    Article  PubMed  Google Scholar 

  4. Kolodgie, F. D., Burke, A. P., Skorija, K. S., Ladich, E., Kutys, R., Makuria, A. T., et al. (2006). Lipoprotein-associated phospholipase a2 protein expression in the natural progression of human coronary atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 2523–2529.

    Article  PubMed  CAS  Google Scholar 

  5. Menschikowski, M., Hagelgans, A., & Siegert, G. (2006). Secretory phospholipase A2 of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins & Other Lipid Mediators, 79, 1–33.

    Article  CAS  Google Scholar 

  6. Daugherty, A., Dunn, J. L., Rateri, D. L., & Heinecke, J. W. (1994). Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. The Journal of Clinical Investigation, 94, 437–444.

    Article  PubMed  CAS  Google Scholar 

  7. Li, D., & Mehta, J. L. (2005). Oxidized LDL, a critical factor in atherogenesis. Cardiovascular Research, 68, 353–354.

    Article  PubMed  CAS  Google Scholar 

  8. Mallat, Z., Benessiano, J., Simon, T., Ederhy, S., Sebella-Arguelles, C., Cohen, A., et al. (2007). Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the Epic–Norfolk study. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 1177–1183.

    Article  PubMed  CAS  Google Scholar 

  9. Koenig, W., Vossen, C. Y., Mallat, Z., Brenner, H., Benessiano, J., & Rothenbacher, D. (2009). Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. European Heart Journal, 30, 2742–2748.

    Article  PubMed  CAS  Google Scholar 

  10. Mallat, Z., Lambeau, G., & Tedgui, A. (2010). Lipoprotein-associated and secreted phospholipases a in cardiovascular disease: roles as biological effectors and biomarkers. Circulation, 122, 2183–2200.

    Article  PubMed  Google Scholar 

  11. Hamilos, M., Muller, O., Cuisset, T., Ntalianis, A., Chlouverakis, G., Sarno, G., et al. (2009). Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angiographically equivocal left main coronary artery stenosis. Circulation, 120, 1505–1512.

    Article  PubMed  Google Scholar 

  12. Ryan, T. J., Faxon, D. P., Gunnar, R. M., Kennedy, J. W., King, S. B., 3rd, Loop, F. D., et al. (1988). Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation, 78, 486–502.

    Article  PubMed  CAS  Google Scholar 

  13. De Bruyne, B., & Sarma, J. (2008). Fractional flow reserve: a review: invasive imaging. Heart, 94, 949–959.

    Article  PubMed  Google Scholar 

  14. Muller, O., Mangiacapra, F., Ntalianis, A., Verhamme, K. M., Trana, C., Hamilos, M., et al. (2011). Long-term follow-up after fractional flow reserve-guided treatment strategy in patients with an isolated proximal left anterior descending coronary artery stenosis. JACC Cardiovasc Interv., 4, 1175–1182.

    Article  PubMed  Google Scholar 

  15. Kuroda, J., & Sadoshima, J. (2010). NADPH oxidase and cardiac failure. Journal of Cardiovascular Translational Research, 3, 314–320.

    Article  PubMed  Google Scholar 

  16. Parenica, J., Nemec, P., Tomandl, J., Ondrasek, J., Pavkova-Goldbergova, M., Tretina, M., et al. (2012). Prognostic utility of biomarkers in predicting of one-year outcomes in patients with aortic stenosis treated with transcatheter or surgical aortic valve implantation. PloS One, 7, e48851.

    Article  PubMed  CAS  Google Scholar 

  17. Pijls, N. H., De Bruyne, B., Peels, K., Van der Voort, P. H., Bonnier, H. J., Bartunek, J. K. J. J., et al. (1996). Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. The New England Journal of Medicine, 334, 1703–1708.

    Article  PubMed  CAS  Google Scholar 

  18. De Bruyne, B., Pijls, N. H., Bartunek, J., Kulecki, K., Bech, J. W., De Winter, H., et al. (2001). Fractional flow reserve in patients with prior myocardial infarction. Circulation, 104, 157–162.

    Article  PubMed  Google Scholar 

  19. Pijls, N. H., Van Gelder, B., Van der Voort, P., Peels, K., Bracke, F. A., Bonnier, H. J., et al. (1995). Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation, 92, 3183–3193.

    Article  PubMed  CAS  Google Scholar 

  20. Wijns, W., Kolh, P., Danchin, N., Di Mario, C., Falk, V., Folliguet, T., et al. (2010). Guidelines on myocardial revascularization. European Heart Journal, 31, 2501–2555.

    Article  PubMed  Google Scholar 

  21. Tonino, P. A., De Bruyne, B., Pijls, N. H., Siebert, U., Ikeno, F., Van’ t Veer, M., FAME Study Investigators, et al. (2009). Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. The New England Journal of Medicine, 360, 213–224.

    Article  PubMed  CAS  Google Scholar 

  22. Pijls, N. H., van Schaardenburgh, P., Manoharan, G., Boersma, E., Bech, J. W., van't Veer, M., et al. (2007). Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the defer study. Journal of the American College of Cardiology, 49, 2105–2111.

    Article  PubMed  Google Scholar 

  23. Puymirat, E., Peace, A., Mangiacapra, F., Conte, M., Ntarladimas, Y., Bartunek, J., et al. (2012). Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary revascularization in patients with small-vessel disease. Circulation. Cardiovascular Interventions, 5, 62–68.

    Article  PubMed  Google Scholar 

  24. De Bruyne, B., Pijls, N. H., Kalesan, B., Barbato, E., Tonino, P. A., Piroth, Z., et al. (2012). Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. The New England Journal of Medicine, 367, 991–1001.

    Article  PubMed  Google Scholar 

  25. Melikian, N., De Bondt, P., Tonino, P., De Winter, O., Wyffels, E., Bartunek, J., et al. (2010). Fractional flow reserve and myocardial perfusion imaging in patients with angiographic multivessel coronary artery disease. JACC. Cardiovascular Interventions, 3, 307–314.

    Article  PubMed  Google Scholar 

  26. Beller, G. A., & Heede, R. C. (2011). SPECT imaging for detecting coronary artery disease and determining prognosis by noninvasive assessment of myocardial perfusion and myocardial viability. Journal of Cardiovascular Translational Research, 4, 416–424.

    Article  PubMed  Google Scholar 

  27. Ragosta, M. (2011). Techniques for phenotyping coronary artery disease in the cardiac catheterization laboratory for applications in translational research. Journal of Cardiovascular Translational Research, 4, 385–392.

    Article  PubMed  Google Scholar 

  28. Eshtehardi, P., Luke, J., McDaniel, M. C., & Samady, H. (2011). Intravascular imaging tools in the cardiac catheterization laboratory: comprehensive assessment of anatomy and physiology. Journal of Cardiovascular Translational Research, 4, 393–403.

    Article  PubMed  Google Scholar 

  29. Shaw, L. J., Berman, D. S., Maron, D. J., Mancini, G. B., Hayes, S. W., Hartigan, P. M., et al. (2008). Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (courage) trial nuclear substudy. Circulation, 117, 1283–1291.

    Article  PubMed  Google Scholar 

  30. Gibbons, R. J. (2008). Noninvasive diagnosis and prognosis assessment in chronic coronary artery disease: stress testing with and without imaging perspective. Circulation. Cardiovascular Imaging, 1, 257–269. discussion 269.

    Article  PubMed  Google Scholar 

  31. Casella, G., Leibig, M., Schiele, T. M., Schrepf, R., Seelig, V., Stempfle, H. U., et al. (2004). Are high doses of intracoronary adenosine an alternative to standard intravenous adenosine for the assessment of fractional flow reserve? American Heart Journal, 148, 590–595.

    Article  PubMed  CAS  Google Scholar 

  32. De Luca, G., Venegoni, L., Iorio, S., Giuliani, L., & Marino, P. (2011). Effects of increasing doses of intracoronary adenosine on the assessment of fractional flow reserve. JACC. Cardiovascular Interventions, 4, 1079–1084.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

Emanuel Valentin is an employee of Aterovax.

Funding Sources

Meijer Foundation for Cardiac Research, Aalst, Belgium

Author information

Authors and Affiliations

  1. Cardiovascular Center and Translational Cardiology Unit, Aalst, Belgium

    Olivier Muller, Argyrios Ntalianis, William Wijns, Leen Delrue, Karen Dierickx, Fabio Mangiacapra, Catalina Trana, Michalis Hamilos, Bernard De Bruyne, Emanuele Barbato & Jozef Bartunek

  2. Interventional Cardiology Unit, Department of Cardiology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, Lausanne, Switzerland

    Olivier Muller

  3. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA

    Reto Auer

  4. Department of General Internal Medicine, University of Bern, Bern, Switzerland

    Nicolas Rodondi

  5. Aterovax, Paris, France

    Emmanuel Valentin

  6. Cardiovascular Center and Cardiovascular Research Center, OLV Hospital, Moorselbaan 164, 9300, Aalst, Belgium

    Jozef Bartunek

Authors
  1. Olivier Muller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Argyrios Ntalianis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William Wijns
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Leen Delrue
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Karen Dierickx
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Reto Auer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nicolas Rodondi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fabio Mangiacapra
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Catalina Trana
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michalis Hamilos
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Emmanuel Valentin
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Bernard De Bruyne
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Emanuele Barbato
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Jozef Bartunek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jozef Bartunek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muller, O., Ntalianis, A., Wijns, W. et al. Association of Biomarkers of Lipid Modification with Functional and Morphological Indices of Coronary Stenosis Severity in Stable Coronary Artery Disease. J. of Cardiovasc. Trans. Res. 6, 536–544 (2013). https://doi.org/10.1007/s12265-013-9468-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-013-9468-x

Keywords

Search

Navigation